NuVision Biotherapies Ltd is a UK-based biotechnology research and development start-up that has recently secured $1.3 million. They secure this amount from investors, including Mercia Asset Management PLC, Pioneer Group, and the University of Nottingham. The company is a spin-out of the University of Nottingham, and focuses on developing innovative and cost-effective regenerative therapies for ophthalmology and wound care.

The team at NuVision has experienced researchers and clinicians for the development of new therapies that will have a tangible impact on patient care. The company's technology platform uses stem cells and other regenerative approaches to treat various conditions.

With this funding, NuVision accelerates its research and development efforts. They will bring new therapies to market more quickly.

The company is poised to make a significant impact in the biotechnology industry and the field of regenerative medicine. Its investors are excited about the potential for growth and success. Check this link for more information about the latest funding round: https://founderlodge.com/round/NuVision-Biotherapies-Ltd-raises-1319000-Unknown-2023-03-10-Andrew-Hopkinson-MTA2MTY.